A Phase III, Observer-blind, Randomized Study to Evaluate the Immunogenicity and Safety of Fluarix (GlaxoSmithKline Biologicals) Compared With Fluzone (Aventis Pasteur) Administered Intramuscularly in Adults 18 Years and Older in the U.S.

Trial Profile

A Phase III, Observer-blind, Randomized Study to Evaluate the Immunogenicity and Safety of Fluarix (GlaxoSmithKline Biologicals) Compared With Fluzone (Aventis Pasteur) Administered Intramuscularly in Adults 18 Years and Older in the U.S.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 23 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top